Lymphoma

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

I have lived with both depression and cancer and know that illness, visible or not, ebbs and flows; canceled plans can reflect health limits, not rejection

Patients with relapsed/refractory diffuse large B-cell lymphoma who received Epkinly alone experienced an improvement in progression-free survival.

Now that I have been living with my chronic cancer for 16 and a half years, I’ve been reflecting on how my attitude has changed over time.

I reflect on the support and love that carried me through my sister’s cancer and her death, expressing deep gratitude this Thanksgiving.

Adding Monjuvi and Revlimid to standard chemotherapy helped patients with newly diagnosed lymphoma live longer without disease worsening.

I reflect on caregiving, loss and gratitude, honoring the people who supported me through my sister’s cancer and my first Thanksgiving without her.

It’s been two-and-a-half years since I “rang the bell” on the Oncology ward, signaling that I had ended my chemotherapy treatment.

The FDA granted review to a supplemental biologics license application for Opdivo plus chemo for previously untreated stage 3/4 classical Hodgkin lymphoma.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

I believe time to be a gift, and as such, my sister was gifted more than a decade despite a terminal illness, and I do have gratitude for that.

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.

I want to appreciate and acknowledge the one person who has had a profoundly positive impact on me throughout my 16-year journey with chronic small lymphocytic lymphoma.

MB-105 received a special FDA status to help deliver faster treatment options for people with relapsed T-cell lymphoma who have few options.